303 related articles for article (PubMed ID: 31754756)
1. Predicting the intervention threshold for initiating osteoporosis treatment among postmenopausal women in China: a cost-effectiveness analysis based on real-world data.
Cui L; He T; Jiang Y; Li M; Wang O; Jiajue R; Chi Y; Xu Q; Xing X; Xia W
Osteoporos Int; 2020 Feb; 31(2):307-316. PubMed ID: 31754756
[TBL] [Abstract][Full Text] [Related]
2. Evaluation on the cost-effective threshold of osteoporosis treatment on elderly women in China using discrete event simulation model.
Ni W; Jiang Y
Osteoporos Int; 2017 Feb; 28(2):529-538. PubMed ID: 27581955
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of FRAX®-based intervention thresholds for management of osteoporosis in Singaporean women.
Chandran M; Ganesan G; Tan KB; Reginster JY; Hiligsmann M
Osteoporos Int; 2021 Jan; 32(1):133-144. PubMed ID: 32797250
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis.
Tian L; Luo C; Li YF; Wang QY; Qu XL; Yue C; Xu LL; Yang YY; Sheng ZF
Arch Osteoporos; 2023 Jul; 18(1):100. PubMed ID: 37460858
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Intervention Thresholds for the Treatment of Osteoporosis Based on FRAX(®) in Portugal.
Marques A; Lourenço Ó; Ortsäter G; Borgström F; Kanis JA; da Silva JA
Calcif Tissue Int; 2016 Aug; 99(2):131-41. PubMed ID: 27016370
[TBL] [Abstract][Full Text] [Related]
6. Which injected antiosteoporotic medication is worth paying for? A cost-effectiveness analysis of teriparatide, zoledronate, ibandronate, and denosumab for postmenopausal osteoporotic women in China.
You R; Mori T; Ke L; Wan Y; Zhang Y; Luo F; Feng D; Yu G; Liu J
Menopause; 2021 Dec; 29(2):210-218. PubMed ID: 34930866
[TBL] [Abstract][Full Text] [Related]
7. The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.
Borgström F; Ström O; Coelho J; Johansson H; Oden A; McCloskey EV; Kanis JA
Osteoporos Int; 2010 Mar; 21(3):495-505. PubMed ID: 19565175
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis.
Borgström F; Ström O; Coelho J; Johansson H; Oden A; McCloskey E; Kanis JA
Osteoporos Int; 2010 Feb; 21(2):339-49. PubMed ID: 19513577
[TBL] [Abstract][Full Text] [Related]
9. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.
Kanis JA; McCloskey EV; Johansson H; Strom O; Borgstrom F; Oden A;
Osteoporos Int; 2008 Oct; 19(10):1395-408. PubMed ID: 18751937
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of antiosteoporosis strategies for postmenopausal women with osteoporosis in China.
Li N; Zheng B; Liu M; Zhou H; Zhao L; Cai H; Huang J
Menopause; 2019 Aug; 26(8):906-914. PubMed ID: 30994577
[TBL] [Abstract][Full Text] [Related]
11. Cost-effective intervention thresholds against osteoporotic fractures based on FRAX® in Switzerland.
Lippuner K; Johansson H; Borgström F; Kanis JA; Rizzoli R
Osteoporos Int; 2012 Nov; 23(11):2579-89. PubMed ID: 22222755
[TBL] [Abstract][Full Text] [Related]
12. Cost-effective osteoporosis treatment thresholds in Greece.
Makras P; Athanasakis K; Boubouchairopoulou N; Rizou S; Anastasilakis AD; Kyriopoulos J; Lyritis GP
Osteoporos Int; 2015 Jul; 26(7):1949-57. PubMed ID: 25740208
[TBL] [Abstract][Full Text] [Related]
13. Setting the new FRAX reference threshold without bone mineral density in Chinese postmenopausal women.
Liu S; Chen R; Ding N; Wang Q; Huang M; Liu H; Xie Z; Ou Y; Sheng Z
J Endocrinol Invest; 2021 Feb; 44(2):347-352. PubMed ID: 32495298
[TBL] [Abstract][Full Text] [Related]
14. Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Ström O; Jönsson B; Kanis JA
Osteoporos Int; 2013 Apr; 24(4):1491-502. PubMed ID: 23224141
[TBL] [Abstract][Full Text] [Related]
15. FRAX® based intervention thresholds for management of osteoporosis in Singaporean women.
Chandran M; McCloskey EV; Thu WPP; Logan S; Hao Y; Tay D; Ang WC; Aung TKK; Choo KS; Ali A; Yan SX; Huang XF; Liu XM; Yong EL; Lekamwasam S
Arch Osteoporos; 2018 Nov; 13(1):130. PubMed ID: 30456726
[TBL] [Abstract][Full Text] [Related]
16. Comparative cost-effectiveness of bazedoxifene and raloxifene in the treatment of postmenopausal osteoporosis in Europe, using the FRAX algorithm.
Kim K; Svedbom A; Luo X; Sutradhar S; Kanis JA
Osteoporos Int; 2014 Jan; 25(1):325-37. PubMed ID: 24114398
[TBL] [Abstract][Full Text] [Related]
17. Effect of abaloparatide on vertebral, nonvertebral, major osteoporotic, and clinical fractures in a subset of postmenopausal women at increased risk of fracture by FRAX probability.
McCloskey EV; Fitzpatrick LA; Hu MY; Williams G; Kanis JA
Arch Osteoporos; 2019 Feb; 14(1):15. PubMed ID: 30719589
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective.
Borgström F; Ström O; Kleman M; McCloskey E; Johansson H; Odén A; Kanis JA
Osteoporos Int; 2011 Mar; 22(3):955-65. PubMed ID: 20532482
[TBL] [Abstract][Full Text] [Related]
19. Screening for and treatment of osteoporosis: construction and validation of a state-transition microsimulation cost-effectiveness model.
Si L; Winzenberg TM; Jiang Q; Palmer AJ
Osteoporos Int; 2015 May; 26(5):1477-89. PubMed ID: 25567776
[TBL] [Abstract][Full Text] [Related]
20. Comparison of strategies for setting intervention thresholds for Chinese postmenopausal women using the FRAX model.
Liu SY; Huang M; Chen R; Ding N; Liu H; Xie ZJ; Sheng ZF; Luo BH; Ou YN
Endocrine; 2019 Jul; 65(1):200-206. PubMed ID: 31111436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
